Baron, Jeffrey
Sävendahl, Lars
De Luca, Francesco
Dauber, Andrew
Phillip, Moshe
Wit, Jan M.
Nilsson, Ola
Article History
First Online: 6 October 2015
Competing interests
: J.B. is listed as a co-inventor on a patent application by the NIH for targeted treatment of cartilage disorders. L.S. has received speakers' honoraria and/or research support from Ferring, Merck Serono, Novo Nordisk and Pfizer, and has submitted a patent application for novel peptides to treat bone or cartilage disorders and other diseases. A.D. has been a faculty speaker at continuing medical education symposia sponsored by Ipsen, Novo Nordisk and Sandoz. M.P. has received research support from Novo Nordisk, Pfizer and Teva, personal fees from Novo Nordisk and is a director of NG Solutions. J.M.W. has served as a consultant for Ammonett, Biopartners, Merck Serono, OPKO, Pfizer, Teva and Versartis, and has received speakers' honoraria from Lilly, Merck Serono, Pfizer, Sandoz and Versartis. O.N. has received a European Society for Paediatric Endocrinology research fellowship sponsored by Novo Nordisk and speaker's honoraria from Lilly. F.D.L. has no competing interests to declare.